Denali Therapeutics Inc. $DNLI Shares Purchased by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its holdings in Denali Therapeutics by 86.7%, acquiring an additional 52,568 shares, bringing their total ownership to approximately $1.54 million.
• Denali Therapeutics reported a quarterly EPS of ($0.72), exceeding analysts' expectations, while sell-side analysts predict an average EPS of ($2.71) for the current year.
• Institutional investors collectively own 92.92% of Denali Therapeutics, while insider transactions indicate significant stock sales, including CEO Ryan J. Watts selling over 495,000 shares.

Trexquant Investment LP lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 86.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 113,224 shares of the company's stock after buying an additional 52,568 shares during the period. Trexquant Investment LP owned approximately 0.08% of Denali Therapeutics worth $1,539,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its position in shares of Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after buying an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Denali Therapeutics in the 1st quarter worth approximately $41,000. GF Fund Management CO. LTD. purchased a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $62,000. Point72 Hong Kong Ltd purchased a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $65,000. Finally, GAMMA Investing LLC grew its position in shares of Denali Therapeutics by 253.8% in the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock worth $108,000 after buying an additional 5,705 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Stock Performance

NASDAQ DNLI traded up $0.18 on Thursday, hitting $14.82. 1,502,280 shares of the company's stock traded hands, compared to its average volume of 1,916,940. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33. The firm's 50-day moving average price is $14.60 and its two-hundred day moving average price is $14.48. The firm has a market capitalization of $2.17 billion, a PE ratio of -5.29 and a beta of 1.23.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the firm earned ($0.59) EPS. As a group, analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, insider Carole Ho sold 2,937 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider directly owned 217,391 shares in the company, valued at approximately $2,952,169.78. The trade was a 1.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 2,937 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider owned 242,346 shares of the company's stock, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 501,962 shares of company stock worth $7,520,799. Company insiders own 12.50% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on DNLI shares. Bank of America cut their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Morgan Stanley dropped their target price on shares of Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday, August 18th. Cantor Fitzgerald reissued an "overweight" rating on shares of Denali Therapeutics in a research report on Monday. Finally, TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research report on Monday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $33.50.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.